Mechanistic studies on the role of ARID2 in hepatocellular carcinoma and lung cancer have shown that an ARID2 loss drives transcriptional reprogramming and impairs the DNA-damage response pathways [55, 56]. This evidence concerns the gene ARID2 and hepatocellular carcinoma.